MedPage Today) — CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09…
ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer

Leave a Comment Leave a Comment